



ASX RELEASE

21 May 2018

Securities to be released from Voluntary Escrow

Noxopharm Limited (“**NOX**” or the “**Company**”) (ASX: NOX) advises that in accordance with ASX Listing Rule 3.10A, the following securities are due for release from voluntary escrow:

Security Description	Number	Date of Release
Ordinary Shares	5,970,714	14 June 2018

The aforesaid Ordinary Shares being released from escrow (representing approximately 4.90% of the Company’s shares) are currently quoted on the ASX and as such quotation of these shares will not be required.

David Franks
P: +61 2 9299 9690
E: dfranks@fa.com.au

ABOUT NOXOPHARM LIMITED

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy and chemotherapy. NOX66 is the first pipeline product.